**Appendix Table E114. Results from studies assessing the ability of miscellaneous platelet function tests to predict bleeding events in patients with ischemic heart disease**

| **Author, year**  **UID**  **Country**  **Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)**  **[statistical test]** | **Adjusted?**  **[YES/NO/NR]**  **If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Dziewierze, 2005  15815794  Poland  NR | Clopidogrel LD 300 mg, 75mg maintain dose | Platelet aggregation inhibition | Haematoma | Haematoma | In hospital stay | Non-responder | Haematoma | 1/7  (14.3) | OR=3.8 (calculate) | NR | NS (>0.05)  non-responder vs. responder | NR | NR |  |
|  |  |  |  |  |  | Responder |  | 1/24  (4.2) |  |  |  |  |  |  |
| Mobley, 2004  14969622  USA  NONE | 300mg LD Clopidogrel and 75mg MD | Combination of LTA, TEG & Ichor Platelet Works | Moderate bleeding perioperatively after CABG | 5.7 g/dl decrease in hemoglobin plus 600 ml of total chest tube drainage in one patient, and the other had a 3.8 g/dl decrease in hemoglobin plus 840 ml of total chest tube drainage | During procedure | Nonresponder | Yes | 2/2 | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | Responder | Yes | NA |  |  |  |  |  |  |
|  |  |  | Life-threatening bleeding complications | Fatal hemorrhage, reduction in hemoglobin of 5 g/dl, hypotension requiring inotropic support, symptomatic intracranial hemorrhage, or transfusion of >4 U of packed red blood cells occurred | During procedure | Nonresponder | Yes | 0/15 | OR=2.3 (calculated) | NR | p=0.68 nonresponder vs. responder  Fisher’s exact test | NR | NR |  |
|  |  |  |  |  |  | Responder | Yes | 0/35 |  |  |  |  |  |  |
|  |  |  | Major bleeding | intraocular hemorrhage causing visual impairment, a decrease in hemoglobin concentration of 2 to 5 g/dl, hemorrhage requiring transfusion of 2 to 4 U of packed red blood cells, and bleeding requiring surgical intervention, including elective pseudoaneurysm repair | During procedure | Nonresponder | Yes | 0/15 | OR=0.4 (calculate) | NR | p=0.59  nonresponder vs. responder  Fisher’s exact test | NR | NR |  |
|  |  |  |  |  |  | Responder | Yes | 2/35 |  |  |  |  |  |  |
|  |  |  | Minor bleeding | bleeding, not otherwise classiﬁed, that necessitated discontinuation of the study drug, a decrease in hemoglobin of <2 g/dl, hemorrhage requiring transfusion of <2 U of packed red blood cells, or development of a groin hematoma requiring prolonged hospitalization, surgical drainage, or a blood transfusion | During procedure | Nonresponder | Yes | 1/15 | OR=2.4 (calculate) | NR | p=0.54 nonresponder vs. responder  Fisher’s exact test | NR | NR |  |
|  |  |  |  |  |  | Responder | Yes | 1/35 |  |  |  |  |  |  |